USX:CTSO - CytoSorbents Corp Cytosorbents Corporation
Sector: Health Care, Industry: Health Care Equipment
Next Earnings: 1 Aug 2022
Add to Watchlist
   
Add Alert 


Yahoo Finance

USD 1.87    -0.13 (-6.50%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

24 May 2022


Loading...
Loading...
Loading...

General

CEO: Dr. Phillip P. Chan M.D., Ph.D.

IPO: 2013-11-07

Headquarters: US

Employees: 221

Homepage

Description

CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend and others. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending. Geographically it derives substantial revenue from product sales in Germany.

Your Holdings
Dashboard
Portfolio
Options
Other Assets

Tools
Screener
Risk Manager
Other Assets
Watchlist
Alerts
Notes
Wall
Community
Forum
Blogs
Instagram
Facebook
Shared Portfolios
Shared Screeners

Collab
Tiger Brokers x StocksCafe
Saxo Trading x StocksCafe
Kenny REIT Screener

Help
Quickstart Guides
StocksCafe Academy
StocksCafe Youtube Channel

About StocksCafe
Our Story
Send Feedback
Pricing
Market
Singapore
Hong Kong
Tokyo
Kuala Lumpur
United States
London
Shenzhen
Shanghai
Bombay
National (India)
Indexes
Singapore Savings Bonds
CoinGecko
Your Account
Settings
Subscriptions
Referrals
Messages
Profile
IG    FB    YouTube

About · FAQs · StocksCafe © 2022 · Privacy · Terms